A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

NCT01505530 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: LY2495655
DRUG: Placebo
DRUG: Standard of Care Chemotherapy

Sponsor

Eli Lilly and Company